Medicine guide
Goprelto
40 mg/mL · Solution
- Prescription only
- Controlled substance · CII
- Active substance
- Cocaine Hydrochloride
- Made by
- LXO US Inc.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
At a glance
Quoted from the official label · 2024-11-06
Used for
- GOPRELTO (cocaine hydrochloride) nasal solution is indicated for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in
The label’s usual adult dose
Adults The recommended dose of GOPRELTO is two soaked cottonoid pledgets placed in each nasal cavity, equivalent to 40 mg cocaine hydrochloride per pledget, for a total dose of 160 mg for four pledgets. The total dose for any one procedure or surgery should not exceed 160 mg, or 3 mg/kg, cocaine hydrochloride. The recommended size of cottonoid pledgets for use with GOPRELTO measure 1.3 cm x 4 cm (sold separately). 2.3 Preparation and Administration of GOPRELTO Pledgets Pour the full contents of one 4 mL (160 mg) bottle of GOPRELTO into a small container. Soak four cottonoid pledgets until the solution is fully absorbed. Following soaking, place two pledgets in each nasal cavity against the septum. Leave pledgets in place for up to twenty minutes. Remove pledgets and continue with the procedure.Discard pledgets and dispose of any unused portion of solution in accordance with institutional procedures for CII products.
Full directions ↓Serious warning
ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence [see Warning and Precautions (5.1) . ] WARNING:
All warnings ↓Good to know
- Prescription only
- Controlled substance (schedule II) — extra rules apply to prescribing and refills
- FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02
Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed
What it is for
- GOPRELTO (cocaine hydrochloride) nasal solution is indicated for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in
- adults.
- GOPRELTO (cocaine hydrochloride) nasal solution is an ester local anesthetic indicated for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in
- adults.
- ( 1 )
From the official label · 2024-11-06 · DailyMed
How it works
From this product’s own US prescribing label.
12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Cocaine hydrochloride is a local anesthetic of the ester type.
No clinically relevant QTc prolongation was observed at the highest clinically relevant concentrations with a single therapeutic dose. 12.3 Pharmacokinetics Absorption The pharmacokinetics of GOPRELTO (cocaine hydrochloride) nasal solution have been assessed in 74 healthy adult subjects across 4 studies.
Half-life1.0–1.7 h
Mostly cleared after≈ 6.8 hfive half-lives — our arithmetic
How the body breaks it down
Cocaine has been described in literature to be primarily metabolized and inactivated by nonenzymatic ester hydrolysis and hepatic carboxylesterase 1 to form benzoylecgonine (BE), and by plasma cholinesterase and hepatic carboxylesterase 2 to form ecgonine methyl ester (EME).
How it leaves the body
Less than 10% of the administered dose is excreted unchanged in the urine.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2024-11-06
Serious warning
The strongest warning the FDA requires. It is printed in a box at the top of the label.
- ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence [see Warning and Precautions (5.1) . ] WARNING:
- ABUSE AND DEPENDENCE See full prescribing information for complete boxed warning.
- CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence.
- (5.1)
Quoted from the official label, section “Boxed Warning”.
Do not take it if
- GOPRELTO is contraindicated in patients with a known history of hypersensitivity to cocaine hydrochloride, other ester-based anesthetics, or any other component of the product.
- Known hypersensitivity to cocaine hydrochloride, other ester-based anesthetics, or any other component of GOPRELTO.
- ( 4 )
Quoted from the official label, section “Contraindications”.
How to take it
These directions are for this exact strength and form. Another one is different.
- For intranasal use only. ( 2.1 )
- Recommended dose:
- two pledgets, each containing 40 mg of cocaine hydrochloride,applied to each nasal cavity. ( 2.2 )
- Do not apply to damaged nasal mucosa. ( 2.1 )
- Preparation and Application:
- In a small container, soak four pledgets in the full contents (4 mL) of one bottle of GOPRELTO until the solution is fully absorbed. Each pledget absorbs 1 mL of solution, equivalent to 40 mg cocaine hydrochloride. ( 2.2 , 2.3 ) – Following soaking, place two pledgets in each nasal cavity against the septum. ( 2.3 ) – Leave pledgets in p lace for up to 20 minutes. ( 2.3 ) 2.1 Important Dosage and Administration Instructions
- GOPRELTO is for intranasal use only.
- Do not apply GOPRELTO to damaged nasal mucosa. 2.2 Dosing Recommendation for
- Adults The recommended dose of GOPRELTO is two soaked cottonoid pledgets placed in each nasal cavity, equivalent to 40 mg cocaine hydrochloride per pledget, for a total dose of 160 mg for four pledgets. The total dose for any one procedure or surgery should not exceed 160 mg, or 3 mg/kg, cocaine hydrochloride. The recommended size of cottonoid pledgets for use with GOPRELTO measure 1.3 cm x 4 cm (sold separately). 2.3 Preparation and Administration of GOPRELTO Pledgets Pour the full contents of one 4 mL (160 mg) bottle of GOPRELTO into a small container. Soak four cottonoid pledgets until the solution is fully absorbed. Following soaking, place two pledgets in each nasal cavity against the septum. Leave pledgets in place for up to twenty minutes. Remove pledgets and continue with the procedure.Discard pledgets and dispose of any unused portion of solution in accordance with institutional procedures for CII products.
Quoted from the official label, section “Dosage & Administration”.
Other warnings
- Seizures :
- GOPRELTO may lower the convulsive threshold. Monitor patients for development of seizures. ( 5.2 )
- Monitor vital signs, including heart rate and rhythm, in patients after receiving GOPRELTO.
- Avoid use of GOPRELTO in patients with a recent or active history of uncontrolled hypertension, unstable angina, myocardial infarction, coronary artery disease, or congestive heart failure. ( 5.3 ) 5.1 Potential for Abuse and Dependence Central nervous system (CNS) stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence [ see Drug Abuse and Dependence ( 9.2 , 9.3 )]. 5.2 Seizures It has been reported in the literature that cocaine hydrochloride may lower the convulsive threshold. The risk may be higher in patients with a history of seizures or in patients with prior electroencephalogram (EEG) abnormalities without seizures, but has been reported in patients with no prior history or EEG evidence of seizures. Monitor patients for development of seizures. 5.3 Blood Pressure and Heart Rate Increases As reported in the literature, cocaine hydrochloride causes an increase in observed blood pressure and heart rate. In the Phase 3 clinical study with GOPRELTO, increases in blood pressure and heart rate were observed for 60 minutes or longer following pledget removal. Monitor for vital sign changes, including heart rate and rhythm, after administration of GOPRELTO.
- Avoid use of GOPRELTO in patients with a recent or active history of uncontrolled hypertension, unstable angina, myocardial infarction, coronary artery disease, or congestive heart failure.
- Avoid use of additional vasoconstrictor agents such as epinephrine or phenylephrine with GOPRELTO. If concomitant use is unavoidable, prolonged vital sign and ECG monitoring may be required [see Drug Interactions ( 7 )]. 5.4 Toxicology Screening The cocaine hydrochloride in GOPRELTO may be detected in plasma for up to one week after administration. Cocaine hydrochloride and its metabolites may be detected in urine toxicology screening for longer than one week after administration.
Quoted from the official label, section “Warnings”.
Pregnancy and breastfeeding
- IN SPECIFIC POPULATIONS
- Pregnancy : May cause fetal harm. ( 8.1 )
- Lactation : Avoid breastfeeding for 48 hours after treatment. ( 8.2 )
- Hepatic Impairment :
- Monitor for adverse reactions such as headache, epistaxis, and clinically- relevant increases in heart rate or blood pressure. Do not administer a second dose within 24 hours of the first dose. ( 8.7 ) 8.1 Pregnancy Risk Summary In animal studies conducted in accordance with good laboratory practices, malformations including vertebral and rib abnormalities were reported when pregnant rabbits were treated with 16 mg/kg cocaine hydrochloride during organogenesis (8 times the adult human exposure following administration of pledgets containing 160 mg of cocaine) and increased pup mortality was noted when pregnant rats were exposed to cocaine hydrochloride during pregnancy at 47 times the adult human AUC exposures. Published rodent studies testing high exposures to cocaine during organogenesis report various malformations at 17 to 34 times the adult human AUC exposures following administration of pledgets containing 160 mg of cocaine. Data Human Data There are no available data on the use of intranasal cocaine hydrochloride solution in pregnant women to inform a drug-associated risk adverse developmental outcomes. There are published data describing adverse developmental outcomes in women with chronic cocaine abuse during pregnancy. The published case-control and observational studies examining the effect of in utero cocaine exposure on fetal growth parameters, after controlling for confounding variables, found exposure was associated with reduced fetal growth compared with non-drugabuse populations. Published data from a large number of studies of women with chronic cocaine abuse during pregnancy are inconsistent in their findings with regard to other developmental outcomes. Prospective studies controlling for polydrug use (marijuana, alcohol, tobacco) and lifestyle factors, have not demonstrated any association between cocaine abuse and specific major or minor fetal anomalies or other forms of fetal harm (premature birth, stillbirth, miscarriage, low birth weight, reduced head circumference, or placental abruption). The applicability of the findings from these studies of chronic abuse in pregnancy to a single topical exposure is limited. Animal Data No clear evidence of fetal malformations was noted in a study where pregnant rats were treated subcutaneously with up to 30 mg/kg cocaine hydrochloride (48 times the human adult exposure based on AUC following administration of pledgets containing 160 mg of cocaine) from Gestation Day 7 through 17 in the absence of overt maternal rat toxicity. However, a single high-dose fetus was reported with both meningoencephalocele and anophthalmia (unilateral). Malformations, including vertebral and rib anomalies, were observed when pregnant rabbits were treated subcutaneously with 16 mg/kg cocaine hydrochloride (8 times the human adult exposure based on AUC exposures following administration of pledgets containing 160 mg of cocaine) from Gestation Day 7 through 20. This dose level was associated with evidence of maternal toxicity (convulsions, decreased body weight gain). No adverse effects were noted in animals treated with 8 mg/kg (1.5 times the adult human AUC following administration of pledgets containing 160 mg of cocaine). An increased incidence of pup mortality between Postnatal Day (PND) 0 to PND 4 and decreased pup body weights from PND 1 to PND 21 were noted when pregnant rats were treated from GD 6 through Lactation Day 20 with 20 mg/kg cocaine hydrochloride (47 times the adult human AUC following administration of pledgets containing 160 mg of cocaine) in the absence of overt maternal toxicity. There was no adverse effect on pre- or postnatal development at 6 mg/kg (7 times the human adult AUC exposure following administration of pledgets containing 160 mg cocaine). Published studies in pregnant mice suggest that high exposure to cocaine (approximately 17-32 times the adult human AUC following administration of pledgets containing 160 mg of cocaine) produced adverse fetal effects including:
- exencephaly, cerebral hemorrhage,hydrocephalus, immaturely developed cerebral ventricles, limb anomalies, incomplete bone ossification, hydronephrosis, cryptorchidism, dilated or cystic ureters, and cleft lip/palate. In a published nonhuman primate study, no adverse effects on physical development or cognitive function were noted after 1 mg/kg cocaine was administered via intramuscular injection three times a day (TID) (approximately 5 times the adult human AUC following administration of pledgets containing 160 mg of cocaine). However, higher exposures to cocaine decreased body weights, overall body length and crown circumference of offspring from pregnant Rhesus monkeys treated with escalating doses up to 7.5 mg/kg cocaine TID intramuscularity per day for 5 days per week from prior to conception to term (39 times the adult human AUC following administration of pledgets containing 160 mg of cocaine). 8.2 Lactation Risk Summary Based on limited case reports in published literature, cocaine is present in human milk at widely varying concentrations. Based on its pharmacochemical characteristics, high concentrations of cocaine are expected in breast milk with systemic exposure. The applicability of these findings to a single topical exposure with limited systemic absorption is unclear. No studies have evaluated cocaine concentrations in milk after topical administration of GOPRELTO. Cocaine is detected in human breastmilk in chronic abuse situations and is expected to be at higher concentrations in milk than in maternal blood based on its physicochemical characteristics. Breastfeeding immediately after administration of GOPRELTO could result in infant plasma concentrations that are approximately half the anticipated maximum maternal plasma concentrations at the clinical dose of 160 mg. The effects of this cocaine plasma concentration in an infant are unknown, but no level of cocaine exposure is considered safe for a breastfed infant. Adverse reactions have occurred in infants ingesting cocaine through breastmilk, including vomiting, diarrhea, convulsions, hypertension, tachycardia, agitation and irritability. The longterm effects on infants exposed to cocaine through breast milk are unknown. There are no data on the effects of GOPRELTO on milk production. Because of the potential for serious adverse reactions in breastfed infants, advise nursing women that breastfeeding is not recommended during treatment with GOPRELTO and to pump and discard breastmilk for 48 hours after use of GOPRELTO. 8.4 Pediatric Use The safety and effectiveness of GOPRELTO in pediatric patients (17 years of age and younger) has not been evaluated. Animal Data Adverse CNS-related clinical signs within the first several days of dosing and decreased body weights were observed when juvenile rat pups were dosed subcutaneously with 25 mg/kg cocaine hydrochloride (15 and 32 times the adult human AUC exposure following administration of pledgets containing 160 mg of cocaine for males and females, respectively) from PND 7 to PND 28. No adverse effects were noted in pups dosed with 12.5 mg/kg (7 times the adult human AUC exposure following administration of pledgets containing 160 mg of cocaine). A single mortality (male) and transient CNS signs were observed in male and female juvenile rat pups that were dosed subcutaneously up to 25 mg/kg cocaine hydrochloride (113 times the adult human AUC exposure) from PND 28 to PND 56. No adverse effects were noted in male pups dosed with 12.5 mg/kg or female pups dosed with 25 mg/kg (84 and 117 times the adult human AUC exposure following administration of pledgets containing 160 mg of cocaine respectively). 8.5 Geriatric Use Of the total number of subjects in the Phase 3 study, 12.1% of those who received GOPRELTO were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience and pharmacokinetic data [see Clinical Pharmacology ( 12.3 )] has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. 8.6 Renal Impairment No dosage adjustment of GOPRELTO is needed in patients with mild, moderate, or severe renal impairment [ see Clinical Pharmacology ( 12.3 )]. 8.7 Hepatic Impairment No dosage adjustment of GOPRELTO is needed in patients with hepatic impairment. Monitor patients with hepatic impairment for adverse reactions such as headache, epistaxis, and clinically- relevant increases in heart rate or blood pressure and do not administer a second dose of GOPRELTO to these patients within 24 hours of the first dose [ see Clinical Pharmacology ( 12.3 )]. 8.8 Patients with Reduced Plasma Cholinesterase Activity Cocaine has been described in literature to be primarily metabolized and inactivated by nonenzymatic ester hydrolysis and hepatic carboxylesterase, and also by plasma cholinesterase, hepatic carboxylesterase and CYP3A4 [see Clinical Pharmacology ( 12.3 )]. Pharmacokinetics of GOPRELTO in patients with reduced plasma cholinesterase activity has not been studied. Genetic abnormalities of plasma cholinesterase (e.g., patients who are heterozygous or homozygous for atypical plasma cholinesterase gene), disease conditions such as malignant tumors, severe liver or kidney disease, decompensated heart disease, infections, burns, anemia, peptic ulcer, or myxedema or other physiological states such as pregnancy may lead to reduced plasma cholinesterase activity. Patients with reduced plasma cholinesterase (pseudocholinesterase) activity may have reduced clearance and increased exposure of plasma cocaine after administration of GOPRELTO. Since cocaine is metabolized by multiple enzymes, the effect of reduced plasma cholinesterase activity on cocaine exposure may be limited. No dosage adjustment of GOPRELTO is needed in patients with reduced plasma cholinesterase. Monitor patients with reduced plasma cholinesterase activity for adverse reactions such as headache, epistaxis, and clinically-relevant increases in heart rate or blood pressure.
Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.
Other medicines
- Disulfiram :
- Increases plasma cocaine exposure.
- Avoid using GOPRELTO in patients taking disulfiram. ( 7 )
- Epinephrine, Phenylephrine :
- There have been reports of myocardial ischemia, myocardial infarction, and ventricular arrhythmias with concomitant use during nasal surgery.
- Avoid use of additional vasoconstrictor agents with GOPRELTO. If concomitant use is unavoidable, prolonged vital sign and ECG monitoring may be required. ( 5.3 , 7 ) 7.1 Disulfiram Published literature reported that disulfiram treatment increased plasma cocaine exposure, including both AUC and C max , by several fold after acute intranasal cocaine administration. Other literature reported that co-administration of disulfiram increased AUC of plasma cocaine by several fold after intravenous cocaine administration [see Clinical Pharmacology ( 12.3 )].
- Avoid using GOPRELTO in patients taking disulfiram. Consider using other local anesthetic agents. 7.2 Epinephrine, Phenylephrine There are reports in the published literature of myocardial ischemia, myocardial infarction, and ventricular arrhythmias after concomitant administration of topical intranasal cocaine with epinephrine and phenylephrine during nasal and sinus surgery.
- Avoid use of additional vasoconstrictor agents such as epinephrine and phenylephrine with GOPRELTO during nasal and sinus surgery. If concomitant use is unavoidable, prolonged vital sign and ECG monitoring may be required [see Warnings and Precautions ( 5.3 ) ]. 7.3 Inhibitors of plasma cholinesterase (pseudocholinesterase) Cocaine has been described in literature to be primarily metabolized and inactivated by nonenzymatic ester hydrolysis and hepatic carboxylesterase, and also by plasma cholinesterase, hepatic carboxylesterase, and CYP3A4 [see Clinical Pharmacology ( 12.3 )]. The pharmacokinetics of GOPRELTO in patients with reduced plasma cholinesterase activity has not been studied. Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, or glucocorticoids. It may also be diminished by administration of irreversible plasma cholinesterase inhibitors such as echothiophate, organophosphate insecticides, and certain antineoplastic agents. Patients with reduced plasma cholinesterase (pseudocholinesterase) activity may have reduced clearance and increased exposure of plasma cocaine after administration of GOPRELTO. Since cocaine is metabolized by multiple enzymes, the effect of reduced plasma cholinesterase activity on cocaine exposure may be limited. No dosage adjustment of GOPRELTO is needed in patients with reduced plasma cholinesterase. Monitor patients with reduced plasma cholinesterase activity for adverse reactions such as headache, epistaxis, and clinically-relevant increases in heart rate or blood pressure.
Quoted from the official label, section “Drug Interactions”.
If you take too much
In an emergency, call your local emergency number or a poison control centre.
- No cases of overdose with GOPRELTO were reported in clinical trials.
- Blood pressure and heart rate increases were greater with cocaine hydrochloride solution 8% than with GOPRELTO.
- In the case of an overdose, consult with a certified poison control center (1-800-222-1222) for up-to-date guidance and advice for treatment of overdosage.
- Individual patient response to cocaine varies widely.
- Toxic symptoms may occur idiosyncratically at low doses.
- Manifestations of cocaine overdose associated with illicit use of cocaine reported in literature and based on reports in FDA’s Adverse Events Reporting System (AERS) database include death, cardio-respiratory arrest, cardiac arrest, respiratory arrest, tachycardia, myocardial infarction, agitation, aggression, restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia, and rhabdomyolysis.
- Fatigue and depression usually follow the central nervous system stimulation.
- Other reactions include arrhythmias, hypertension or hypotension, circulatory collapse, nausea, vomiting, diarrhea, and abdominal cramps.
- Fatal poisoning is usually preceded by convulsions and coma.
- Because cocaine is significantly distributed to tissues and rapidly metabolized, dialysis and hemoperfusion are not effective.
- Acidification of the urine does not significantly enhance cocaine elimination.
Quoted from the official label, section “Overdosage”.
Misuse and dependence
- 9.1 Controlled Substance GOPRELTO contains cocaine, a Schedule II controlled substance.
- 9.2 Abuse GOPRELTO contains cocaine, a substance with a high potential for abuse.
- GOPRELTO can be misused and abused, which can lead to addiction.
- GOPRELTO may also be diverted for abuse purposes [ see Warnings and Precautions ( 5.1 )].
- Drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects.
- Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes:
- a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.
- Drug abuse of a substance may occur without progression to drug addiction. “Drug-seeking” behavior is very common in persons with substance use disorders.
- Drug abuse and addiction are conditions that are separate and distinct from physical dependence and tolerance [see Dependence ( 9.3 )].
- Health care providers should be aware that abuse and addiction may occur in the absence of symptoms indicative of physical dependence and tolerance.
- Individuals who abuse stimulants may use GOPRELTO for abuse purposes.
- Adverse events associated with abuse of cocaine include euphoria, excitation, irritability, restlessness, anxiety, paranoia, confusion, headache, psychosis, hypertension, stroke, seizures, dilated pupils, nausea, vomiting, and abdominal pain.
- Intranasal abuse can produce damage to the nostrils (e.g.,ulceration and deviated septum).
- Abuse of cocaine can result in overdose, convulsions, unconsciousness, coma, and death [ see Overdosage ( 10 )].
- Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.
- GOPRELTO, like all prescription drugs with abuse potential, can be diverted for non-medical use into illicit channels of distribution.
- In order to minimize these risks, effective accounting procedures should be implemented, in addition to routine procedures for handling controlled substances.
- 9.3 Dependence Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.
- GOPRELTO is approved for topical single use during diagnostic procedures and surgeries, so physical dependence and withdrawal symptoms are unlikely to develop.
- Although GOPRELTO is not indicated for chronic therapy, repeated misuse or abuse of this product may lead to physical dependence.
Quoted from the official label, section “Drug Abuse and Dependence”.
Side effects
- The most common adverse reactions (>0.5%) occurring in patients treated with GOPRELTO (cocaine hydrochloride) nasal solution 4% were headache and epistaxis.
- ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact LXO US., INC. at 1-844-800-8007 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
- GOPRELTO has been evaluated in four Phase 1 studies and one Phase 3 study, which included 647 adult subjects who received a single topical intranasal 160 mg dose (four pledgets), of GOPRELTO.
- The randomized, double-blind, controlled Phase 3 study was conducted in adult patients undergoing diagnostic procedures and surgeries on or through the mucous membranes of the nasal cavities, of which 278 received GOPRELTO (4% solution), 275 received cocaine hydrochloride solution 8%, and 95 received placebo.
- Safety was evaluated for up to 7 days after dosing.
- The most commonly reported adverse reactions (>1 patient) to occur in the Phase 3 study with GOPRELTO (4% solution) were headache and epistaxis.
- Two adverse reactions of headache were severe (Table 1).
- No premature discontinuations due to an adverse event, serious adverse events, or deaths were reported in the Phase 3 clinical study.
- Table 1:
- Common Adverse Reactions with GOPRELTO in >1 Patient System Organ Class / Preferred Term GOPRELTO 4% (N=278) Cocaine Hydrochloride Solution 8% (N=275) Placebo (N=95) Nervous System Disorders Headache 7 (3%) 4 (2%) 1 (1%) Respiratory, Thoracic, and Mediastinal Disorders Epistaxis 3 (1%) 2 (1%) 0 Psychiatric Disorders Anxiety 0 2 (1%) 0
Quoted from the official label, section “Adverse Reactions”.
Strengths and forms
- FORMS AND STRENGTHS GOPRELTO (cocaine hydrochloride) nasal solution is provided as a 4% solution, 160 mg/4 mL (40 mg/mL), equivalent to 142.4 mg/4 mL (35.6 mg/mL) cocaine, and is a clear, greencolored solution in a single-unit bottle.
- Nasal solution:
- 160 mg/4 mL (40 mg/mL or 4%) cocaine hydrochloride, equivalent to 142.4 mg/4 mL (35.6 mg/mL) cocaine, in a single-unit bottle.
- ( 3 )
Quoted from the official label, section “Dosage Forms & Strengths”.
What it looks like and how it is packed
- GOPRELTO (cocaine hydrochloride) nasal solution is a clear, green colored liquid available as one dosage strength:
- 160 mg/4 mL (40 mg/mL or 4%) cocaine hydrochloride, equivalent to 142.4 mg/4 mL (35.6 mg/mL) cocaine NDC # 70839-359-04:
- Single-unit 4 mL bottle Store upright at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [ see USP, Controlled Room Temperature (CRT )].
- Avoid freezing.
Quoted from the official label, section “How Supplied”.
What is in it
- GOPRELTO (cocaine hydrochloride) nasal solution for intranasal use contains a 4% solution, 160 mg/4 mL (40 mg/mL), equivalent to 142.4 mg/4 mL (35.6 mg/mL) cocaine, an ester local anesthetic. The chemical name for cocaine hydrochloride is (1R,2R,3S,5S) methyl 3-(benzoyloxy)-8- methyl-8-azabicyclo[3.2.1]octane-2-carboxylate hydrochloride. The molecular formula is C17H21NO4
- HCl and the molecular weight is 339.81. The structural formula is:
- Inactive ingredients are anhydrous citric acid, D&C Yellow No. 10, FD&C Green No. 3, sodium benzoate, and purified water. structure
Quoted from the official label, section “Description”.
Ingredients people check for
Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.
- Colour dyes
D&C Yellow No. 10; FD&C Green No. 3
Some people react to dyes such as tartrazine (Yellow 5) or carmine.
Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.
Every version of this medicine (4)
The same active substance, strength and kind of form, from every company that sells it — with what each label lists.
Hide versions whose label lists:
Showing 4 of 4
Details
| Made by | LXO US Inc. |
|---|---|
| Active substance | Cocaine Hydrochloride |
| Strength | 40 mg/mL |
| Form | Solution |
| Route | Nasal |
| Packs | 1 BOTTLE, GLASS in 1 CARTON / 4 mL in 1 BOTTLE, GLASS |
| NDC | 70839-359 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.